These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31927611)

  • 1. Prospective use of the single-mouse experimental design for the evaluation of PLX038A.
    Ghilu S; Li Q; Fontaine SD; Santi DV; Kurmasheva RT; Zheng S; Houghton PJ
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):251-263. PubMed ID: 31927611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
    Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
    Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
    Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
    Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
    Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
    Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
    Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
    Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single protein encapsulated SN38 for tumor-targeting treatment.
    Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
    J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial testing of cisplatin by the pediatric preclinical testing program.
    Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
    Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
    Kolb EA; Houghton PJ; Kurmasheva RT; Mosse YP; Maris JM; Erickson SW; Guo Y; Teicher BA; Smith MA; Gorlick R
    Pediatr Blood Cancer; 2020 May; 67(5):e28098. PubMed ID: 31975571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
    Nguyen F; Alferiev I; Guan P; Guerrero DT; Kolla V; Moorthy GS; Chorny M; Brodeur GM
    Clin Cancer Res; 2018 Jun; 24(11):2585-2593. PubMed ID: 29514842
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
    Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
    Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of ABT-751 against childhood cancer models in vivo.
    Morton CL; Favours EG; Mercer KS; Boltz CR; Crumpton JC; Tucker C; Billups CA; Houghton PJ
    Invest New Drugs; 2007 Aug; 25(4):285-95. PubMed ID: 17384918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.
    Kurmasheva RT; Erickson SW; Earley E; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28772. PubMed ID: 33089597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
    Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
    PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
    Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
    BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice.
    Jung J; Schneider EL; Zhang W; Song H; Zhang M; Chou W; Meher N; VanBrocklin HF; Barcellos-Hoff MH; Ozawa T; Gilbert MR; Santi DV
    Sci Rep; 2024 Jun; 14(1):14175. PubMed ID: 38898077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.
    Carol H; Reynolds CP; Kang MH; Keir ST; Maris JM; Gorlick R; Kolb EA; Billups CA; Geier B; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2013 Apr; 60(4):633-41. PubMed ID: 22753001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.